Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension

Fig. 4

Effect of maximum ADA titer results on ACR20 response rate and mean DAS28-CRP at week 24 (end of Period I) and week 54 (Period II); a ACR20 response rate, b mean DAS28-CRP, c change in mean DAS28-CRP. ACR American College of Rheumatology, ADA, antidrug antibody, DAS28-CRP disease activity score 28 based on C-reactive protein, F FKB327, RP reference product. Low ADA titer was defined as ≤ the lower quartile, high ADA titer as ≥ the upper quartile, with mid titer between the lower and upper quartiles (both not included)

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us